Pardes Biosciences Appoints Thomas G. Wiggans to CEO and

Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple...

Related Keywords

Pardes Biosciences ,Mark Auerbach ,Stephen Jasper ,Thomasg Wiggans ,Pardes Bioscience ,Eli Lilly ,Tom Wiggans ,University Of Kansas ,Southern Methodist University ,Sangamo Biosciences ,Nasdaq ,Cymabay Therapeutics Inc ,Forma Therapeutics Holdings Inc ,Board Of Directors Connetics Corporation ,Board Of Directors Annexon Inc ,Onyx Pharmaceuticals ,Cytotherapeutics Inc ,Pardes Biosciences Inc ,Exchange Commission ,Board Of Directors Peplin Inc ,Gilmartin Group ,Somaxon Pharmaceuticals Inc ,Chief Scientific ,Strategic Advisor ,Chief Executive Officer ,Yuri Lopatin ,Connetics Corporation ,Stiefel Laboratories ,Chief Operating Officer ,Managing Director ,Forma Therapeutics Holdings ,Somaxon Pharmaceuticals ,Southern Methodist ,Fair Disclosure ,Pardes Bioscience Investors ,Nasdaq Prds ,Nc ,Antiviral ,Coronavirus ,Covid 19 ,Oral Antiviral ,Tardes ,Bi 0451 ,Ars Cov 2 ,